types of glp 1 meds Market Overview: GLP-1 Agonists and the Obesity Market | Blog GLP-1 drugs may have a

Check out what patients are saying about the VCU Health Medical Weight Loss Program

L.LjubisavljevicM

But fiber could get a boost from wider adoption of these drugs, which are making people think more about the connection between the gut and overall health and wellness, said Shimek

In SURMOUNT-1 , a 72-week Phase 3 double-blind trial in 2,539 adults with obesity (or overweight with a complication) but without diabetes, once-weekly tirzepatide produced mean weight changes of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo, with 5057% of participants on the higher doses losing at least 20% of body weight